Register      Login
Microbiology Australia Microbiology Australia Society
Microbiology Australia, bringing Microbiologists together
RESEARCH ARTICLE (Open Access)

Lipids, statins and susceptibility to SARS-CoV-2 and influenza A viruses

Melissa Carabott A , Ryan Case A , Sudip Dhakal A and Ian Macreadie A B
+ Author Affiliations
- Author Affiliations

A School of Science, RMIT University, Bundoora, Vic. 3083, Australia

B Tel.: +61 402 564 308; Email: ian.macreadie@rmit.edu.au

Microbiology Australia 42(2) 87-91 https://doi.org/10.1071/MA21021
Submitted: 30 March 2021  Accepted: 26 April 2021   Published: 17 May 2021

Journal Compilation © The Authors 2021 Open Access CC BY, published (by CSIRO Publishing) on behalf of the ASM

Abstract

The extensive and on-going epidemiology studies of the SARS-CoV-2 pandemic have raised interesting observations on statins reducing COVID-19 severity. In this review, literature is analysed to examine how statins affect COVID-19 and influenza A, another pandemic respiratory virus. This information could be useful to prevent or reduce disease severity caused by respiratory viruses.

The respiratory viruses, influenza A virus (IAV) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), have demonstrated their action to cause significant morbidity, mortality and socio-economic disruption. The 1918 influenza pandemic caused 20–100 million deaths, with one-third of the world’s population being infected1, while the current COVID-19 pandemic has resulted in 146 million confirmed cases and over 3 million deaths to date2. Our focus here is to review the potential for statins to affect patient outcomes for these viral infections.


Statins and cholesterol

Statins are among the most highly prescribed drugs used in the treatment of hypercholesterolemia, a major cause of cardiovascular disease. Diet has an effect on cholesterol levels, but our endogenous synthesis of cholesterol accounts for age-associated increases. To reduce plasma cholesterol to medically recommended levels of less than 4 mM, doctors prescribe statins to inhibit 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR) (Figure 1). Cholesterol is essential so it is important that statins do not block cholesterol synthesis completely. As shown in Figure 1, inhibition of HMGCR also affects other L-mevalonate pathways including protein prenylation3. Interestingly, statins can target any HMGCR, including HMGCRs of pathogenic Candida species and Aspergillus fumigatus4.


Figure 1.  Molecular targets of statin treatment during SARS-CoV-2 infection showing inhibition of HMG-CoA reductase resulting in multiple effects.
Click to zoom

Statins were discovered in the soil fungus Aspergillus terreus, which is currently used to produce lovastatin, a precursor of simvastatin. Simvastatin and atorvastatin were the first blockbuster drugs, but many additional statins have since been produced. Statins are used to inhibit HMGCR in the liver, reducing plasma cholesterol levels. Cholesterol is also an essential component of cell membranes, which become integrated into viral envelopes, leading us to review what is known about the effect of statins on SARS-CoV-2 and the other respiratory virus associated with pandemics, influenza A virus (IAV). Our findings are summarised in Table 1.


Table 1.  Effects of cholesterol and statins on SARS-CoV-2 and IAV infections.
Click to zoom

Cholesterol levels

Cholesterol is a vital part of IAV and SARS-CoV-2. During viral budding, lipids and cholesterol from infected host cells become part of the viral envelope19. Dietary cholesterol levels were shown to affect influenza infection in a mouse study7. Compared to a controlled diet group, mice with a 2% cholesterol diet experienced increased morbidity over a 5-week period.

The underlying low-grade chronic inflammation due to the release of the pro-inflammatory mediators from adipocytes of obese individuals exacerbates the cytokine storm observed in COVID-19 disease20. Obesity is also associated with the upregulation of ACE2 expression. ACE2 is a receptor for SARS-CoV-2 spike proteins, so its upregulation could further enhance viral attachment and entry to the host tissue and increase severity21. The higher content of lipid rafts with high cholesterol levels in obese patients may also support SARS-CoV-2 attachment to host cells and its subsequent replication. Importantly, cholesterol-rich lipid rafts in the host cell membrane are favourable for enveloped viruses making cholesterol reduction a general strategy to thwart enveloped virus infection22.

Effect of statins

Statins have been investigated to determine whether they affect outcomes of IAV and SARS-CoV-2 infections. While benefits of atorvastatin and rosuvastatin have been demonstrated in a model of IAV infection in cell culture14,15, the benefits to statin users have varied. A study comparing 5181 statin users with 5181 non-users found small benefits that were not statistically significant16. On the other hand, in a large-scale matched cohort study (n = 76 232), moderate dose usage of statin was found beneficial by significantly reducing the risk of death due to COPD and influenza18. Similarly, in another multistate surveillance study, statin usage in patients hospitalised due to influenza was found associated with reduced mortality17. As influenza induces pro-inflammatory pathways by triggering the innate immune system, the anti-inflammatory pleotropic properties of statins have been studied to counteract it. Through in vitro tests, statins were able to inhibit IAV proliferation and possibly reduce inflammation by targeting Rho/Rho kinase pathways14. Several studies of patients with SARS-CoV-2 infection demonstrated the beneficial effects of statins, significantly reducing mortality rates and disease severity912.

Mechanisms and thoughts on future therapeutics

It is now clear that statins have several additional effects apart from cholesterol synthesis inhibition which deserves further investigation.


Conclusion

Statins show promise in reducing severity of IAV and SARS-CoV-2, which could be attributed to inhibition HMGCR and a number of other targets. Specifically, the inhibition of protein prenylation has multiple effects including enhancing cytokine-induced inflammation, regulating proteostasis, and post-translational modifications of the intracellular proteins. These events are most likely to be involved in SARS-CoV-2 pathogenesis and viral proliferation as the virus utilises host machinery for survival and proliferation. Knowledge of the targeting of statins may improve the development of therapies for COVID-19 and IAV.


Conflicts of interest

Ian Macreadie is the Editor-in-Chief of Microbiology Australia, but was blinded from the peer-review process for this paper.


Declaration of funding

This study did not receive specific funding.



References

[1]  Selleck, P. and Bernard, R. (2020) The 1918 Spanish influenza pandemic: plus ça change, plus c’est la même chose. Microbiol. Aust. 41, 177–182.
The 1918 Spanish influenza pandemic: plus ça change, plus c’est la même chose.Crossref | GoogleScholarGoogle Scholar |

[2]  WHO (2021) WHO Coronavirus (COVID-19) Dashboard. https://covid19.who.int/ (accessed 26 April 2021).

[3]  Zeiser, R. (2018) Immune modulatory effects of statins. Immunology 154, 69–75.
Immune modulatory effects of statins.Crossref | GoogleScholarGoogle Scholar | 29392731PubMed |

[4]  Westermeyer, C. and Macreadie, I.G. (2007) Simvastatin reduces ergosterol levels, inhibits growth and causes loss of mtDNA in Candida glabrata. FEMS Yeast Res. 7, 436–441.
Simvastatin reduces ergosterol levels, inhibits growth and causes loss of mtDNA in Candida glabrata.Crossref | GoogleScholarGoogle Scholar | 17257373PubMed |

[5]  Kočar, E. et al. (2021) Cholesterol, lipoproteins, and COVID-19: basic concepts and clinical applications. Biochim. Biophys. Acta (BBA) – Mol. Cell Biol. Lipids 1866, 158849.
Cholesterol, lipoproteins, and COVID-19: basic concepts and clinical applications.Crossref | GoogleScholarGoogle Scholar |

[6]  Sun, X. and Whittaker, G.R. (2003) Role for influenza virus envelope cholesterol in virus entry and infection. J. Virol. 77, 12543.
Role for influenza virus envelope cholesterol in virus entry and infection.Crossref | GoogleScholarGoogle Scholar | 14610177PubMed |

[7]  Louie, A.Y. et al. (2020) Dietary cholesterol affects the pathogenesis of influenza A virus infection in mice. J. Immunol. 204, 93.19.

[8]  Bajimaya, S. et al. (2017) Cholesterol is required for stability and infectivity of influenza A and respiratory syncytial viruses. Virology 510, 234–241.
Cholesterol is required for stability and infectivity of influenza A and respiratory syncytial viruses.Crossref | GoogleScholarGoogle Scholar | 28750327PubMed |

[9]  Kow, C.S. and Hasan, S.S. (2020) Meta-analysis of effect of statins in patients with COVID-19. Am. J. Cardiol. 134, 153–155.
Meta-analysis of effect of statins in patients with COVID-19.Crossref | GoogleScholarGoogle Scholar | 32891399PubMed |

[10]  Zhang, X.-J. et al. (2020) In-hospital use of statins is associated with a reduced risk of mortality among individuals with COVID-19. Cell Metab. 32, 176–187.e4.
In-hospital use of statins is associated with a reduced risk of mortality among individuals with COVID-19.Crossref | GoogleScholarGoogle Scholar | 32592657PubMed |

[11]  Torres-Peña, J.D. et al. (2021) Prior treatment with statins is associated with improved outcomes of patients with COVID-19: data from the SEMI-COVID-19 registry. Drugs 81, 685–95.
| 33782908PubMed |

[12]  Permana, H. et al. (2021) In-hospital use of statins is associated with a reduced risk of mortality in coronavirus-2019 (COVID-19): systematic review and meta-analysis. Pharmacol. Rep. 1–12.

[13]  Reiner, Ž. et al. (2020) Statins and the COVID-19 main protease: in silico evidence on direct interaction. AMS 16, 490–496.
Statins and the COVID-19 main protease: in silico evidence on direct interaction.Crossref | GoogleScholarGoogle Scholar | 32399094PubMed |

[14]  Mehrbod, P. et al. (2014) Mechanisms of action and efficacy of statins against influenza. BioMed Res. Int. 2014, 872370.
Mechanisms of action and efficacy of statins against influenza.Crossref | GoogleScholarGoogle Scholar | 25478576PubMed |

[15]  Episcopio, D. et al. (2019) Atorvastatin restricts the ability of influenza virus to generate lipid droplets and severely suppresses the replication of the virus. FASEB J. 33, 9516–9525.
Atorvastatin restricts the ability of influenza virus to generate lipid droplets and severely suppresses the replication of the virus.Crossref | GoogleScholarGoogle Scholar | 31125254PubMed |

[16]  Brassard, P. et al. (2017) The effect of statins on influenza-like illness morbidity and mortality. Pharmacoepidemiol. Drug Saf. 26, 63–70.
The effect of statins on influenza-like illness morbidity and mortality.Crossref | GoogleScholarGoogle Scholar | 27686457PubMed |

[17]  Vandermeer, M.L. et al. (2012) Association between use of statins and mortality among patients hospitalized with laboratory-confirmed influenza virus infections: a multistate study. J. Infect. Dis. 205, 13–19.
Association between use of statins and mortality among patients hospitalized with laboratory-confirmed influenza virus infections: a multistate study.Crossref | GoogleScholarGoogle Scholar | 22170954PubMed |

[18]  Frost, F.J. et al. (2007) Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins. Chest 131, 1006–1012.
Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins.Crossref | GoogleScholarGoogle Scholar | 17426203PubMed |

[19]  Musiol, A. et al. (2013) Annexin A6-balanced late endosomal cholesterol controls influenza A replication and propagation. MBio 4, e00608-13.
Annexin A6-balanced late endosomal cholesterol controls influenza A replication and propagation.Crossref | GoogleScholarGoogle Scholar | 24194536PubMed |

[20]  Kim, J. and Nam, J.-H. (2020) Insight into the relationship between obesity-induced low-level chronic inflammation and COVID-19 infection. Int. J. Obes. 44, 1541–1542.
Insight into the relationship between obesity-induced low-level chronic inflammation and COVID-19 infection.Crossref | GoogleScholarGoogle Scholar |

[21]  Banerjee, M. et al. (2020) Obesity and COVID-19: a fatal alliance. Indian J. Clin. Biochem. 35, 410–417.
Obesity and COVID-19: a fatal alliance.Crossref | GoogleScholarGoogle Scholar |

[22]  Rawat, S.S. et al. (2003) Modulation of entry of enveloped viruses by cholesterol and sphingolipids Mol. Membr. Biol. 20, 243–254.
Modulation of entry of enveloped viruses by cholesterol and sphingolipidsCrossref | GoogleScholarGoogle Scholar | 12893532PubMed |

[23]  Dhakal, S. and Macreadie, I. (2021) Genes of SARS-CoV-2 and emerging variants. Microbiol. Aust. 42, 10–12.
Genes of SARS-CoV-2 and emerging variants.Crossref | GoogleScholarGoogle Scholar |

[24]  Kneller, D.W. et al. (2020) Structural plasticity of SARS-CoV-2 3CL Mpro active site cavity revealed by room temperature X-ray crystallography. Nat. Commun. 11, 3202.
Structural plasticity of SARS-CoV-2 3CL Mpro active site cavity revealed by room temperature X-ray crystallography.Crossref | GoogleScholarGoogle Scholar | 32581217PubMed |

[25]  Dhakal, S. et al. (2019) Simvastatin efficiently reduces levels of Alzheimer’s amyloid beta in yeast. Int. J. Mol. Sci. 20, 3531.
Simvastatin efficiently reduces levels of Alzheimer’s amyloid beta in yeast.Crossref | GoogleScholarGoogle Scholar |

[26]  Wolozin, B. et al. (2007) Simvastatin is associated with a reduced incidence of dementia and Parkinson’s disease. BMC Med. 5, 20.
Simvastatin is associated with a reduced incidence of dementia and Parkinson’s disease.Crossref | GoogleScholarGoogle Scholar | 17640385PubMed |

[27]  Subir, R. et al. (2020) Pros and cons for use of statins in people with coronavirus disease-19 (COVID-19). Diabetes Metab. Syndr. 14, 1225–1229.
Pros and cons for use of statins in people with coronavirus disease-19 (COVID-19).Crossref | GoogleScholarGoogle Scholar | 32683320PubMed |

[28]  Basso, A.D. et al. (2005) The farnesyl transferase inhibitor (FTI) SCH66336 (lonafarnib) inhibits Rheb farnesylation and mTOR signaling: role in FTI enhancement of taxane and tamoxifen anti-tumour activity. J. Biol. Chem. 280, 31101–31108.
The farnesyl transferase inhibitor (FTI) SCH66336 (lonafarnib) inhibits Rheb farnesylation and mTOR signaling: role in FTI enhancement of taxane and tamoxifen anti-tumour activity.Crossref | GoogleScholarGoogle Scholar | 16006564PubMed |

[29]  Rivas, D. et al. (2007) Inhibition of protein farnesylation arrests adipogenesis and affects PPAR gamma expression and activation in differentiating mesenchymal stem cells. PPAR Res. 2007, 81654.
Inhibition of protein farnesylation arrests adipogenesis and affects PPAR gamma expression and activation in differentiating mesenchymal stem cells.Crossref | GoogleScholarGoogle Scholar | 18274630PubMed |

[30]  Liu, Y. et al. (2020) CB-Dock: a web server for cavity detection-guided protein–ligand blind docking. Acta Pharmacol. Sin. 41, 138–144.
CB-Dock: a web server for cavity detection-guided protein–ligand blind docking.Crossref | GoogleScholarGoogle Scholar | 31263275PubMed |


Biographies

Melissa Jayne Carabott is a Bachelor of Science (Biological Sciences) graduate and is currently completing her Honours degree.

Ryan Case is a Bachelor of Biotechnology graduate with a major in microbiology. He is currently completing a Bachelor of Environmental Science degree.

Sudip Dhakal is a final year PhD candidate and Casual staff at School of Science, RMIT University, who is involved in learning and teaching activities within the school. His research focuses on searching for strategies to overcome the reduced proteostasis during Alzheimer’s disease using yeast as model system.

Ian Macreadie is an Honorary Professor at RMIT University and Editor-in-Chief of Microbiology Australia. His research and expertise are in diverse field of biosciences ranging from industrial microbiology to biomedical research.